Oncologix Tech Stock Performance

OCLG Stock  USD 0.0001  0.00  0.00%   
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Oncologix Tech are completely uncorrelated.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Oncologix Tech has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable essential indicators, Oncologix Tech is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
  

Oncologix Tech Relative Risk vs. Return Landscape

If you would invest  0.01  in Oncologix Tech on November 16, 2025 and sell it today you would earn a total of  0.00  from holding Oncologix Tech or generate 0.0% return on investment over 90 days. Oncologix Tech is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Oncologix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  

Oncologix Tech Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncologix Tech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncologix Tech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Oncologix Tech generated a negative expected return over the last 90 days
Oncologix Tech has some characteristics of a very speculative penny stock
Oncologix Tech has a very high chance of going through financial distress in the upcoming years
Oncologix Tech currently holds 3.97 M in liabilities. Oncologix Tech has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncologix Tech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncologix Tech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncologix Tech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncologix to invest in growth at high rates of return. When we think about Oncologix Tech's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 2.85 M. Net Loss for the year was (2.37 M) with profit before overhead, payroll, taxes, and interest of 614.41 K.
Oncologix Tech currently holds about 86.31 K in cash with (24.2 K) of positive cash flow from operations.

Oncologix Tech Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncologix Pink Sheet often depends not only on the future outlook of the current and potential Oncologix Tech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncologix Tech's indicators that are reflective of the short sentiment are summarized in the table below.
Short Long Term Debt5.2 M
Shares Float736.6 M

Oncologix Tech Fundamentals Growth

Oncologix Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Oncologix Tech, and Oncologix Tech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncologix Pink Sheet performance.

About Oncologix Tech Performance

By analyzing Oncologix Tech's fundamental ratios, stakeholders can gain valuable insights into Oncologix Tech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Oncologix Tech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncologix Tech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana. Oncologix Tech operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 191 people.

Things to note about Oncologix Tech performance evaluation

Checking the ongoing alerts about Oncologix Tech for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Oncologix Tech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Oncologix Tech generated a negative expected return over the last 90 days
Oncologix Tech has some characteristics of a very speculative penny stock
Oncologix Tech has a very high chance of going through financial distress in the upcoming years
Oncologix Tech currently holds 3.97 M in liabilities. Oncologix Tech has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncologix Tech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncologix Tech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncologix Tech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncologix to invest in growth at high rates of return. When we think about Oncologix Tech's use of debt, we should always consider it together with cash and equity.
The entity reported the previous year's revenue of 2.85 M. Net Loss for the year was (2.37 M) with profit before overhead, payroll, taxes, and interest of 614.41 K.
Oncologix Tech currently holds about 86.31 K in cash with (24.2 K) of positive cash flow from operations.
Evaluating Oncologix Tech's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Oncologix Tech's pink sheet performance include:
  • Analyzing Oncologix Tech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncologix Tech's stock is overvalued or undervalued compared to its peers.
  • Examining Oncologix Tech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Oncologix Tech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncologix Tech's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Oncologix Tech's pink sheet. These opinions can provide insight into Oncologix Tech's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Oncologix Tech's pink sheet performance is not an exact science, and many factors can impact Oncologix Tech's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Oncologix Pink Sheet analysis

When running Oncologix Tech's price analysis, check to measure Oncologix Tech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncologix Tech is operating at the current time. Most of Oncologix Tech's value examination focuses on studying past and present price action to predict the probability of Oncologix Tech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncologix Tech's price. Additionally, you may evaluate how the addition of Oncologix Tech to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
CEOs Directory
Screen CEOs from public companies around the world